Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical drug development for childhood cancer.
Moreno L, Chesler L, Hargrave D, Eccles SA, Pearson AD. Moreno L, et al. Among authors: pearson ad. Expert Opin Drug Discov. 2011 Jan;6(1):49-64. doi: 10.1517/17460441.2011.537652. Epub 2010 Nov 24. Expert Opin Drug Discov. 2011. PMID: 22646826
Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development.
Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, Viana-Pereira M, Jones TA, Williams RD, Grigoriadis A, Vassal G, Workman P, Sheer D, Reis RM, Pearson AD, Hargrave D, Jones C. Bax DA, et al. Among authors: pearson ad. PLoS One. 2009;4(4):e5209. doi: 10.1371/journal.pone.0005209. Epub 2009 Apr 14. PLoS One. 2009. PMID: 19365568 Free PMC article.
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stávale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C. Bax DA, et al. Among authors: pearson ad. Clin Cancer Res. 2009 Sep 15;15(18):5753-61. doi: 10.1158/1078-0432.CCR-08-3210. Epub 2009 Sep 8. Clin Cancer Res. 2009. PMID: 19737945
MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.
Gaspar N, Marshall L, Perryman L, Bax DA, Little SE, Viana-Pereira M, Sharp SY, Vassal G, Pearson AD, Reis RM, Hargrave D, Workman P, Jones C. Gaspar N, et al. Among authors: pearson ad. Cancer Res. 2010 Nov 15;70(22):9243-52. doi: 10.1158/0008-5472.CAN-10-1250. Epub 2010 Oct 8. Cancer Res. 2010. PMID: 20935218 Free PMC article.
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RE. Berry T, et al. Among authors: pearson ad. Cancer Cell. 2012 Jul 10;22(1):117-30. doi: 10.1016/j.ccr.2012.06.001. Cancer Cell. 2012. PMID: 22789543 Free PMC article.
Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.
Jamin Y, Tucker ER, Poon E, Popov S, Vaughan L, Boult JK, Webber H, Hallsworth A, Baker LC, Jones C, Koh DM, Pearson AD, Chesler L, Robinson SP. Jamin Y, et al. Among authors: pearson ad. Radiology. 2013 Jan;266(1):130-40. doi: 10.1148/radiol.12120128. Epub 2012 Nov 20. Radiology. 2013. PMID: 23169794 Free PMC article.
Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience.
Moreno L, Vaidya SJ, Pinkerton CR, Lewis IJ, Imeson J, Machin D, Pearson AD; European Neuroblastoma Study Group; Children's Cancer and Leukaemia Group (CCLG) (formerly UKCCSG). Moreno L, et al. Among authors: pearson ad. Pediatr Blood Cancer. 2013 Jul;60(7):1135-40. doi: 10.1002/pbc.24452. Epub 2012 Dec 31. Pediatr Blood Cancer. 2013. PMID: 23281263 Clinical Trial.
About the benefits of immunotherapy for high-risk neuroblastoma.
Moreno L, Barone G, Park JR, Pearson AD. Moreno L, et al. Among authors: pearson ad. J Clin Oncol. 2013 Feb 10;31(5):649-50. doi: 10.1200/JCO.2012.47.4080. Epub 2013 Jan 7. J Clin Oncol. 2013. PMID: 23295791 No abstract available.
How can attrition rates be reduced in cancer drug discovery?
Moreno L, Pearson AD. Moreno L, et al. Among authors: pearson ad. Expert Opin Drug Discov. 2013 Apr;8(4):363-8. doi: 10.1517/17460441.2013.768984. Epub 2013 Feb 4. Expert Opin Drug Discov. 2013. PMID: 23373702
New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.
Barone G, Anderson J, Pearson AD, Petrie K, Chesler L. Barone G, et al. Among authors: pearson ad. Clin Cancer Res. 2013 Nov 1;19(21):5814-21. doi: 10.1158/1078-0432.CCR-13-0680. Epub 2013 Aug 21. Clin Cancer Res. 2013. PMID: 23965898 Free PMC article. Review.
400 results